Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies-Reference-Cited by-同舟云学术

Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies

Published:2024-08-27 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Akhtar Othman Salim¹^ORCID,Szabo Aniko²,Bhatlapenumarthi Vineel¹,Forsberg Mark³,Balev Metodi⁴,Patwari Anannya¹,Cheruvalath Heloise⁵,Bhutani Divaya⁴^ORCID,Thanendrarajan Sharmilan⁶,Dhakal Binod¹^ORCID,Zangari Maurizio⁶^ORCID,Patel Tanvi⁶,Shrestha Asis⁶,Al‐Hadidi Samer⁶^ORCID,Cooper Dennis³,Lentzsch Suzanne⁴,van Rhee Frits⁶,Shah Mansi R.⁷,Bag Aishee⁷,D'Souza Anita¹^ORCID,Schinke Carolina⁶,Chakraborty Rajshekhar⁴,Shah Nishi³^ORCID,Mohan Meera¹^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

2. Division of Biostatistics, Institute of Health and Equity Medical College of Wisconsin Milwaukee Wisconsin USA

3. Division of Hematological Malignancies, Department of Oncology Montefiore Medical Center and Albert Einstein College of Medicine New York New York USA

4. Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center Columbia University New York New York USA

5. Medical College of Wisconsin Medical School Milwaukee Wisconsin USA

6. Myeloma Center University of Arkansas for Medical Science Little Rock Arkansas USA

7. Division of Blood Disorders Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA

Abstract

SummaryThe Glasgow prognostic score (GPS) and CAR‐HEMATOTOX (CAR‐HT) score identify multiple myeloma (MM) patients at high risk for immune‐mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T‐cell redirecting bispecific antibodies (bsAb) is unclear. This multi‐centre retrospective study examines the association of baseline GPS and CAR‐HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high‐risk CAR‐HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.

Funder

Medical College of Wisconsin Cancer Center

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19700

Reference18 articles.

1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

3. Teclistamab in Relapsed or Refractory Multiple Myeloma

4. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

5. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma